Navigation Links
Tianyin to Present at 5th Annual Biomedical Forum by Sino American BioPharmaceutical Association
Date:4/21/2010

CHENGDU, Sichuan, China, April 21 /PRNewswire-Asia-FirstCall/ -- Tianyin Pharmaceutical (NYSE Amex: TPI) was invited by Sino American Biopharmaceutical Association (SABPA) to present at its 5th Annual Biomedical Forum held at Irvine, California on April 24th, 2010. SABPA Biomedical forum focuses on innovations in pharmaceutical and biotechnology industries, as well as business opportunities to thrive in the new economy. The forum provides an attractive platform for entrepreneurs, scientists, investors, executives and policy makers to promote life sciences, biotechnology, pharmaceutical, medical devices and alliances across the biomedical industry.

"We appreciate the invitation by SABPA to interface with a large audience of industrial professionals, entrepreneurs and healthcare investment funds," said Dr. James J. Tong, Chief Financial Officer and Chief Business & Development Officer of Tianyin, "Since 2005, SAPBA conferences have been the forefront to bridge biopharmaceuticals and innovations between the healthcare industry of US and China. We look forward to the in-depth interaction with the biopharmaceutical community in US."

Dr. Jiang, Guoqing, Chairman and CEO of Tianyin Pharmaceutical pointed out, "The past 10 years have seen the rapid expansion of China health care industry, propelled by the economic growth in China, favorable government policies and accelerated demands for pharmaceuticals resulted from an increasing urbanization of a growing population. The ongoing healthcare reform provides further momentum for both generic medicines as well as innovative biopharmaceuticals. Tianyin is positioned to explore the opportunities on both fronts."

SAPBA meeting on 24th of April, McDonald Auditorium, University of California, Irvine from 8:30 am till 4:30 pm (http://www.sabpa.org/web/OCLA/)

About Tianyin Pharmaceuticals

Tianyin Pharmaceutical Co., Inc., headquartered in Chengdu, Sichuan Province of China, is a leading biopharmaceutical company that is engaged in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and branded generics, equipped with two state-of-the-art manufacturing facilities and an extensive nationwide sales and distribution network throughout China. Tianyin currently manufactures and markets a comprehensive portfolio of 50 products, of which 22 are listed in the highly selective National Medicine Catalog of the National Medical Insurance program, 7 are included in the essential drug list of China. Tianyin achieved 10 new drug approvals at SFDA in 2009 and has a pipeline of 12 products pending regulatory approval that target various indications with considerable market potential. Tianyin has an extensive nationwide distribution network with a sales force of 720 sales representatives out of totaled 1,365 employees. For more information about Tianyin, please visit http://www.tianyinpharma.com .

Safe Harbor Statement

The Statements which are not historical facts contained in this press release are forward-looking statements that involve certain risks and uncertainties including but not limited to risks associated with the uncertainty of future financial results, additional financing requirements, development of new products, government approval processes, the impact of competitive products or pricing, technological changes, the effect of economic conditions and other uncertainties detailed in the Company's filings with the Securities and Exchange Commission.

    For more information, please contact:

    Investors Contact:
     James Jiayuan Tong  M.D. Ph.D.
     Chief Financial Officer, Chief Business & Development Officer
     Director
     Tianyin Pharmaceutical Co., Inc.
     Web:   http://www.tianyinpharma.com
     Email: Dr.Tong@tianyinpharma.com
     Tel:   +86-28-8551-6696
            +1-949-350-6999 (U.S.)

    Address:
     23rd Floor Unionsun YangKuo Plaza
     No 2 Block 3 South Renmin Road
     Chengdu, 610041
     China


'/>"/>
SOURCE Tianyin Pharmaceutical Co., Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Tianyin Pharmaceutical, Co. Announces Cash Dividend to Common Shareholders - Record Date October 30, 2009
2. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Ofloxacin and Fleroxacin
3. Tianyin Pharmaceutical co., Inc. Announces Record First Quarter 2010 Financial Results
4. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA New Product Approvals for 2 Generic Products
5. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
6. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
7. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
8. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
9. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
10. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
11. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2017)... , Oct. 2, 2017 The Rebound mobile ... the struggle to reverse the tide of prescription drug addiction. ... regulating their medicine intake and stepping down their dosage in ... to launch in December 2017; the first 100,000 people to ... more at http://www.rebound-solution.com/ ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017  DarioHealth ... and big data solutions, today announced that its MyDario product is expected ... local TV listings for when The Dr. Oz Show airs in your ... The nine-time Emmy ... ...
(Date:9/22/2017)... -- As the latest Obamacare repeal effort moves is debated, ... and Lindsey Graham (R-SC) medical device market ... is in an odd place.  The industry wants repeal ... on medical device sales passed along with the Affordable ... visits and hospital customers with the funding to invest ...
Breaking Medicine Technology:
(Date:10/13/2017)... Fairfax, VA (PRWEB) , ... October 13, 2017 ... ... provider of DevOps and Agile Software Development, has been awarded a contract by ... (EATS) Blanket Purchase Agreement (BPA) aims to accelerate the enterprise use of Agile ...
(Date:10/12/2017)... ... October 12, 2017 , ... First Healthcare ... program management, will showcase a range of technology and learning solutions at the ... Convention and Expo to be held October 14–18, 2017 at the Mandalay Bay ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has ... today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula ... the highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... leader in post-acute health care, have expanded their existing home health joint venture ... , AccentCare has been operating a joint venture home health company with Asante, ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
Breaking Medicine News(10 mins):